These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 14534885)

  • 1. The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Hock BD; McKenzie JL; Patton WN; Haring LF; Yang Y; Shen Y; Estey EH; Albitar M
    Cancer; 2003 Oct; 98(8):1681-8. PubMed ID: 14534885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.
    Hock BD; McKenzie JL; Patton NW; Drayson M; Taylor K; Wakeman C; Kantarjian H; Giles F; Albitar M
    Cancer; 2006 May; 106(10):2148-57. PubMed ID: 16598754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
    Aguayo A; Kantarjian HM; Estey EH; Giles FJ; Verstovsek S; Manshouri T; Gidel C; O'Brien S; Keating MJ; Albitar M
    Cancer; 2002 Nov; 95(9):1923-30. PubMed ID: 12404286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients.
    Hock BD; Patton WN; Budhia S; Mannari D; Roberts P; McKenzie JL
    Leukemia; 2002 May; 16(5):865-73. PubMed ID: 11986949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
    Hu Q; Dey AL; Yang Y; Shen Y; Jilani IB; Estey EH; Kantarjian HM; Giles FJ; Albitar M
    Cancer; 2004 May; 100(9):1884-91. PubMed ID: 15112269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating levels and clinical significance of soluble CD86 in myeloma patients.
    Hock BD; Drayson M; Patton WN; Taylor K; Kerr L; McKenzie JL
    Br J Haematol; 2006 Apr; 133(2):165-72. PubMed ID: 16611307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels of the soluble forms of CD80, CD86, and CD83 are elevated in the synovial fluid of rheumatoid arthritis patients.
    Hock BD; O'Donnell JL; Taylor K; Steinkasserer A; McKenzie JL; Rothwell AG; Summers KL
    Tissue Antigens; 2006 Jan; 67(1):57-60. PubMed ID: 16451202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
    Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
    Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
    Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
    Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.
    van der Straaten HM; van Biezen A; Brand R; Schattenberg AV; Egeler RM; Barge RM; Cornelissen JJ; Schouten HC; Ossenkoppele GJ; Verdonck LF;
    Haematologica; 2005 Oct; 90(10):1339-45. PubMed ID: 16219570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome.
    Meyers CA; Albitar M; Estey E
    Cancer; 2005 Aug; 104(4):788-93. PubMed ID: 15973668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble CD86 protein in serum samples of patients with asthma.
    Shi HZ; Xie ZF; Deng JM; Chen YQ; Xiao CQ
    Thorax; 2004 Oct; 59(10):870-5. PubMed ID: 15454653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
    Kröger N; Brand R; van Biezen A; Cahn JY; Slavin S; Blaise D; Sierra J; Zander A; Niederwieser D; de Witte T;
    Bone Marrow Transplant; 2006 Jan; 37(2):183-9. PubMed ID: 16299545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).
    Graf M; Reif S; Hecht K; Pelka-Fleischer R; Kroell T; Pfister K; Schmetzer H
    Ann Hematol; 2005 May; 84(5):287-97. PubMed ID: 15592672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemic cluster growth in culture is an independent risk factor for acute myeloid leukemia and short survival in patients with myelodysplastic syndrome.
    Bernimoulin M; Stern M; Tichelli A; Jotterand M; Gratwohl A; Nissen C
    Acta Haematol; 2008; 119(4):226-35. PubMed ID: 18566541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
    Loeffler-Ragg J; Germing U; Sperr WR; Herrmann H; Zwierzina H; Valent P; Ulmer H; Stauder R
    Crit Rev Oncol Hematol; 2011 May; 78(2):150-61. PubMed ID: 20580567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
    Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
    Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse.
    Sperr WR; Mitterbauer M; Mitterbauer G; Kundi M; Jäger U; Lechner K; Valent P
    Clin Cancer Res; 2005 Sep; 11(18):6536-43. PubMed ID: 16166430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.